Asthma Flashcards
1
Q
0-4 years old; classification= Symptoms: = <2 days a week Nighttime awakenings: 0 SABA use: = <2 days a week Interference with normal activity: none
A
intermittent
2
Q
0-4 years old; classification= Symptoms: >/=2 days a week Nighttime awakenings: 1-2x/month SABA use: >2 days/week Interference with normal activity: none
A
Mild
3
Q
0-4 years old; classification= Symptoms: daily Nighttime awakenings: 3-4x/month SABA use: daily Interference with normal activity: some limitation
A
moderate
4
Q
0-4 years old; classification= Symptoms: throughout the day Nighttime awakenings: >1x/week SABA use: several times / day Interference with normal activity: extremely limited
A
severe
5
Q
Step 1 tx (0-4 y/o)
A
SABA PRN
6
Q
step 2 tx (0-4 y/o)
A
Low-dose ICS
7
Q
step 3 tx (0-4 y/o)
A
medium-dose ICS
8
Q
step 4 tx (0-4 y/o)
A
medium dose ICS + LABA
9
Q
step 5 tx (0-4 y/o)
A
high dose ICS + LABA
10
Q
step 6 tx (0-4 y/o)
A
high dose ICS + LABA
and
corticosteroids ORAL
11
Q
How controlled? 0-4 y/o Symptoms: = <2 days a week Nighttime awakenings: <1x/month SABA use: = <2 days a week Interference with normal activity: none
A
well controlled
- maintain current tx
- regular follow up q 1-6 months
12
Q
How controlled? 0-4 y/o Symptoms: >2 days a week Nighttime awakenings: >1x/month SABA use: >2 days/week Interference with normal activity: some limitation
A
not well controlled
- step up 1 step
- re-eval 2-6 weeks
13
Q
How controlled? 0-4 y/o Symptoms: throughout the day Nighttime awakenings: >1x/week SABA use: several times / day Interference with normal activity: extremely limited
A
very poorly controlled
- ORAL systemic corticosteroids
- step up 1-2 steps
- re-eval in 2 weeks
14
Q
5-11 years old; classification= Symptoms: = 2 days/week Nighttime awakenings: =2/month SABA use: =2 days/week Interference with normal activity: none
FEV > ___ %
A
intermittent
> 80%
Step 1 : PRN SABA
15
Q
5-11 years old; classification= Symptoms: > 2 days/week Nighttime awakenings: 3-4 x/month SABA use: >2 days/week Interference with normal activity: minor limitation
A
mild
step 2: SABA, low-doseICS
FEV1- >80%